Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PLSE

Pulse Biosciences Inc

Feb 06 • 04:00PM ET

20.75

+7.06 51.57 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Feb 06, 2:00 PMPulse Biosciences unveils late-breaking first-in-human feasibility data for its nPulse Cardiac Catheter System at the 2026 AF Symposium, citing high 6- and 12-month atrial fibrillation ablation success and a favorable safety profile; an SEC filing specifies the feasibility study achieved a 96% one-year success rate.

Peers: CUTR IRTC NVRO ITGR IART ANIK NEO MDXG STER TMDX

| Held by: VTI IWM VXF IWO VTWO SCHA VHT ISMD IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-1.14	Insider Own	74.03%	Shs Outstand	67.74M	Perf Week	50.04%
Market Cap	1.41B	Forward P/E	-	EPS next Y	-1.32	Insider Trans	0.09%	Shs Float	17.60M	Perf Month	36.51%
Enterprise Value	1.32B	PEG	-	EPS next Q	-0.27	Inst Own	8.88%	Short Float	14.61%	Perf Quarter	27.54%
Income	-74.73M	P/S	15624.22	EPS this Y	-61.49%	Inst Trans	0.69%	Short Ratio	14.03	Perf Half Y	40.96%
Sales	0.09M	P/B	15.16	EPS next Y	-29.27%	ROA	-74.06%	Short Interest	2.57M	Perf YTD	51.13%
Book/sh	1.37	P/C	14.77	EPS next 5Y	-10.66%	ROE	-86.99%	52W High	24.70 -15.99%	Perf Year	-15.51%
Cash/sh	1.40	P/FCF	-	EPS past 3/5Y	26.13% 16.53%	ROIC	-75.44%	52W Low	12.56 65.21%	Perf 3Y	534.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-1495.35%	Volatility	14.43% 7.70%	Perf 5Y	-38.86%
Dividend TTM	-	EV/Sales	14654.00	EPS Y/Y TTM	-40.63%	Oper. Margin	-89594.19%	ATR (14)	1.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.01	Sales Y/Y TTM	-	Profit Margin	-86898.84%	RSI (14)	75.19	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.02	EPS Q/Q	-38.58%	SMA20	42.79%	Beta	1.79	Target Price	26.00
Payout	-	Debt/Eq	0.09	Sales Q/Q	-	SMA50	45.61%	Rel Volume	15.31	Prev Close	13.69
Employees	75	LT Debt/Eq	0.07	Earnings	Feb 19 AMC	SMA200	31.38%	Avg Volume	183.37K	Price	20.75
IPO	May 18, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.58% -82.80%	Trades		Volume	2,806,876	Change	51.57%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Initiated	Mizuho	Outperform	$25
Jul-07-25	Initiated	Oppenheimer	Outperform	$22
Jul-27-21	Initiated	Stephens	Overweight	$28
Mar-11-21	Initiated	Maxim Group	Buy	$40
Jan-26-21	Reiterated	H.C. Wainwright	Buy	$16 → $40
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6 → $16
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral	$26 → $6
Feb-25-19	Initiated	H.C. Wainwright	Buy	$27

Feb-06-26 01:58PM	Pulse Biosciences Heart Device Data Fuels Stock Surge (Benzinga) +51.57%
Feb-05-26 07:00PM	Pulse Biosciences Presents Late-Breaking Data from nPulse Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium (Business Wire) -9.40%
Feb-04-26 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026 (Business Wire) +7.62%
Feb-03-26 07:00AM	Pulse Biosciences' nPulse Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium (Business Wire)
Jan-09-26 07:00AM	Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors (Business Wire)
07:00AM	Loading…
Jan-06-26 07:00AM	Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium (Business Wire)
Dec-29-25 04:05PM	Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-19-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.12%
10:25AM	PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial (Zacks)
Dec-18-25 07:00AM	Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation (Business Wire)
Dec-10-25 12:40PM	PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor (Zacks)
Dec-09-25 07:00AM	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Technology (Business Wire)
Nov-21-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-25 04:05PM	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences (Business Wire)
12:03AM	Pulse Biosciences Inc (PLSE) Q3 2025 Earnings Call Highlights: Regulatory Milestones and Early ... (GuruFocus.com)
06:15PM	Loading…
Nov-05-25 06:15PM	Pulse Biosciences, Inc (PLSE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results (Business Wire)
Oct-24-25 07:00AM	Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study (Business Wire)
Oct-22-25 04:05PM	Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025 (Business Wire)
Oct-16-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-13-25 08:14AM	Pulse Biosciences Unveils Promising First-in-Human Data for nPulse (Zacks)
Oct-10-25 07:00AM	Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire) -8.57%
Oct-07-25 07:00AM	Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire)
Oct-01-25 01:40PM	Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial (Insider Monkey)
Sep-17-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 12:24PM	Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study (Zacks)
Sep-10-25 07:00AM	Pulse Biosciences' nPulse Technology to be Featured at the American Thyroid Association 2025 Annual Meeting (Business Wire)
Sep-09-25 07:00AM	Pulse wins IDE approval; Galvanize pulls in $100M (MedTech Dive)
Sep-08-25 07:00AM	Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation (Business Wire)
Sep-04-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:00AM	Loading…
Sep-02-25 07:00AM	Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study (Business Wire)
Aug-27-25 12:25PM	PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment (Zacks) -6.27%
Aug-26-25 07:00AM	Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid (Business Wire)
Aug-13-25 03:12AM	Pulse Biosciences Inc (PLSE) Q2 2025 Earnings Call Highlights: Navigating Increased Expenses ... (GuruFocus.com) +11.19%
Aug-12-25 04:05PM	Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results (Business Wire)
Aug-01-25 07:00AM	Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference (Business Wire)
Jul-29-25 04:05PM	Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025 (Business Wire)
Jul-16-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-23-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-25 03:41AM	Pulse Biosciences Inc (PLSE) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-08-25 04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results (Business Wire)
May-06-25 04:05PM	Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference (Business Wire)
May-01-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting (Business Wire)
Apr-25-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.06%
Apr-24-25 04:05PM	Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025 (Business Wire) +6.00%
Apr-23-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting (Business Wire)
Apr-10-25 01:00PM	Pulse Biosciences: Some Key Questions Remain Unanswered (Seeking Alpha)
10:36AM	Pulse Biosciences: Interesting Product, But No Revenue Stream (Seeking Alpha)
Mar-28-25 08:10AM	Q4 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.00%
03:03AM	Pulse Biosciences Inc (PLSE) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Mar-27-25 07:46PM	Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results (Business Wire)
Mar-26-25 04:05PM	Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference (Business Wire)
Mar-07-25 08:00AM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025 (Business Wire)
Mar-04-25 08:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-25 04:05PM	Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-05-25 09:42AM	Pulse Biosciences names new CFO, continuing string of C-suite changes (MedTech Dive)
Feb-04-25 08:00AM	Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer (Business Wire) +14.84%
Jan-30-25 08:00AM	Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting (Business Wire)
Jan-21-25 01:03PM	Pulse Biosciences touts positive results from PFA early feasibility study (Medical Device Network) +11.16%
07:00AM	Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium (Business Wire)
Jan-13-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium (Business Wire)
Jan-10-25 08:00AM	Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer (Business Wire)
Jan-03-25 09:00AM	Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +10.34%
Dec-23-24 04:30PM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire) +5.34%
Dec-19-24 08:00AM	Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants (Business Wire)
Dec-17-24 08:00AM	Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery (Business Wire)
Oct-31-24 02:25PM	Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association (Business Wire)
01:58PM	Q3 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
05:01AM	Pulse Biosciences Inc (PLSE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-30-24 04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results (Business Wire)
04:02PM	Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology (Business Wire)
Oct-21-24 08:00AM	Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 (Business Wire)
Aug-21-24 07:55AM	Better Cotton Pakistan, PULSE to boost data transparency in cotton farming (Just Style) +13.76%
Aug-13-24 12:38PM	Q2 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +8.05%
Aug-12-24 04:05PM	Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results (Business Wire)
04:01PM	Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors (Business Wire)
Aug-09-24 06:32AM	Pulse Biosciences launches first-in-human pulsed field ablation trial (Medical Device Network)
Aug-08-24 08:00AM	Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System (Business Wire) +9.74%
Aug-01-24 04:05PM	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences (Business Wire)
Jul-29-24 04:05PM	Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024 (Business Wire) -11.36% -5.95%
Jul-09-24 07:27AM	Pulse drops 510(k) plan for PFA device after FDA requests clinical data (MedTech Dive)
06:53AM	Pulse Biosciences receives breakthrough device status for CellFX system (Medical Device Network)
Jul-08-24 08:00AM	Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation (Business Wire) +28.71%
Jul-03-24 02:44PM	Pulse Biosciences, Inc. Announces the Closing of its Rights Offering (Business Wire)
Jun-28-24 08:00AM	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering (Business Wire)
Jun-04-24 08:00AM	Pulse Biosciences, Inc. Announces Commencement of Rights Offering (Business Wire)
May-20-24 05:39PM	Pulse Biosciences Moves New Record Date for Rights Offering (MT Newswires) +9.86% +13.40%
04:05PM	Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 (Business Wire)
May-17-24 06:41AM	Pulse Biosciences names new CEO, reassigns former leader (MedTech Dive)
May-16-24 08:00AM	Pulse Biosciences CellFX Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting (Business Wire) +8.68%
May-14-24 05:17PM	Pulse Biosciences Appoints Burke Barrett as President, CEO (MT Newswires) +7.55% -5.59%
04:05PM	Pulse Biosciences Enhances Executive Leadership Team (Business Wire)
May-13-24 09:02AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:00AM	Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System (Business Wire)
May-08-24 06:06AM	Q1 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -9.21%
03:56AM	Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-07-24 09:56PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024 (InvestorPlace)
05:45PM	Pulse Biosciences Reports Q1 2024 Financial Results Amidst Strategic Business Developments (GuruFocus.com)
04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results (Business Wire)

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Option Exercise	1.53	4,600	7,038	47,898	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Sale	18.53	4,600	85,238	43,298	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Option Exercise	1.53	20,000	30,600	63,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Option Exercise	1.53	400	612	43,698	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Sale	18.49	20,000	369,800	43,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Sale	18.48	400	7,392	43,298	Sep 22 09:24 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Option Exercise	4.00	181,534	726,136	284,406	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Sale	16.28	25,000	407,000	122,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Sale	16.21	20,000	324,200	122,872	Sep 18 08:44 PM
KEVIN DANAHY	Officer	Sep 18 '25	Proposed Sale	16.27	25,000	406,750		Sep 18 04:29 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Sale	15.77	25,000	394,250	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Sale	14.78	25,000	369,500	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Sale	14.32	25,000	358,000	122,872	Sep 15 09:09 PM
DUGGAN ROBERT W	Director	Sep 10 '25	Buy	14.66	34,659	508,101	47,551,200	Sep 12 08:14 PM
DARRIN UECKER	Director	Sep 11 '25	Proposed Sale	14.77	120,000	1,772,400		Sep 11 04:30 PM
UECKER DARRIN	Chief Technology Officer	Jun 12 '25	Sale	16.40	15,000	246,000	137,872	Jun 16 08:23 PM
UECKER DARRIN	Chief Technology Officer	Jun 13 '25	Sale	15.98	15,000	239,700	122,872	Jun 16 08:23 PM
DARRIN UECKER	Officer	Jun 13 '25	Proposed Sale	15.98	15,000	239,740		Jun 13 04:14 PM
DARRIN UECKER	Officer	Jun 12 '25	Proposed Sale	16.40	15,000	246,048		Jun 12 04:25 PM

Open in Screener

SMMT

Summit Therapeutics Inc

Feb 06 • 04:00PM ET

14.99

+1.14 8.23 %

Healthcare • Biotechnology • USA • NASD

SMMT Summit Therapeutics Inc daily Stock Chart

Peers: VRTX REGN GILD NBIX ALNY BIIB AMGN SRPT AKTX PRTA

| Held by: XBI VTI VB VBR VXF IWP IBB VHT IWF IWR

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	86.17%	Shs Outstand	744.44M	Perf Week	3.52%
Market Cap	11.16B	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.20%	Shs Float	102.98M	Perf Month	-21.15%
Enterprise Value	10.93B	PEG	-	EPS next Q	-0.09	Inst Own	13.83%	Short Float	36.12%	Perf Quarter	-17.04%
Income	-921.61M	P/S	-	EPS this Y	-233.75%	Inst Trans	2.77%	Short Ratio	13.94	Perf Half Y	-46.60%
Sales	0.00M	P/B	58.04	EPS next Y	13.33%	ROA	-241.08%	Short Interest	37.20M	Perf YTD	-14.29%
Book/sh	0.26	P/C	46.71	EPS next 5Y	-	ROE	-292.49%	52W High	36.91 -59.39%	Perf Year	-27.86%
Cash/sh	0.32	P/FCF	-	EPS past 3/5Y	31.56% -10.52%	ROIC	-472.69%	52W Low	13.83 8.39%	Perf 3Y	294.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.96% 6.11%	Perf 5Y	115.37%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-348.63%	Oper. Margin	-	ATR (14)	0.89	Perf 10Y	32.07%
Dividend Ex-Date	-	Quick Ratio	3.80	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.11	Recom	1.59
Dividend Gr. 3/5Y	- -	Current Ratio	3.80	EPS Q/Q	-302.84%	SMA20	-6.94%	Beta	-1.38	Target Price	32.43
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-12.66%	Rel Volume	1.01	Prev Close	13.85
Employees	159	LT Debt/Eq	0.01	Earnings	Oct 20 BMO	SMA200	-29.65%	Avg Volume	2.67M	Price	14.99
IPO	Mar 05, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-82.25% -	Trades		Volume	2,692,813	Change	8.23%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Upgrade	Barclays	Underweight → Equal Weight	$18
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Underweight	$13
Sep-04-25	Initiated	Guggenheim	Buy	$40
Aug-19-25	Initiated	Piper Sandler	Neutral	$21
Jul-01-25	Initiated	UBS	Buy	$30
Jun-11-25	Initiated	Leerink Partners	Underperform	$12
Mar-26-25	Upgrade	Citigroup	Neutral → Buy	$23 → $35
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform	$30
Feb-28-25	Initiated	Goldman	Buy	$42
Jan-08-25	Initiated	Truist	Buy	$35
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31
Nov-04-24	Initiated	JMP Securities	Mkt Outperform	$32
Sep-27-24	Downgrade	Citigroup	Buy → Neutral	$19 → $23
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral

Show Previous Ratings

Feb-06-26 08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily) +8.23%
Feb-05-26 07:22AM	FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data (Insider Monkey)
Jan-31-26 07:13PM	2 Stocks That Could Soar This Year (Motley Fool)
Jan-30-26 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.97%
10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
07:50AM	Loading…
07:50AM	Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings (Zacks)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
07:30AM	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy (Business Wire)
05:20AM	Moderna holds a garage sale; Roche defends obesity drug data (BioPharma Dive)
Jan-28-26 06:57AM	Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive (Insider Monkey)
Jan-18-26 12:31PM	Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? (Benzinga)
Jan-15-26 10:20PM	Akeso Confident of Cancer Drug's FDA Approval Odds (Bloomberg)
Jan-12-26 12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga) -13.41%
12:05PM	2 Biotech Stocks That Could Soar This Year (Motley Fool)
06:15AM	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) (Business Wire)
06:00AM	Loading…
06:00AM	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC (Business Wire)
Jan-09-26 08:16PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-26 07:30AM	Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.00%
Jan-02-26 09:10AM	Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst (Insider Monkey)
Dec-29-25 01:53PM	Top Research Reports for Apple, Cisco & IBM (Zacks)
Dec-17-25 09:59AM	Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? (Zacks)
Dec-11-25 07:44AM	Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development (Insider Monkey)
Dec-09-25 05:25PM	2 Stocks Up Over 600% in the Past 3 Years With More Room to Run (Motley Fool) -8.62% +5.41%
11:04AM	MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? (Zacks)
Dec-05-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:25PM	Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? (Motley Fool)
Dec-03-25 04:44AM	Don't Buy Summit Therapeutics Until This Big Thing Happen (Motley Fool) +6.49%
Dec-02-25 07:00AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Nov-27-25 09:45AM	AstraZeneca or Merck: Which Oncology Giant Has the Edge? (Zacks)
Nov-17-25 08:05AM	MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) -5.99%
08:19PM	Loading…
Nov-10-25 08:19PM	Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial (Insider Monkey)
09:48AM	Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3? (Zacks)
Nov-07-25 09:00AM	Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China (Business Wire)
Nov-04-25 07:00AM	Summit Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Oct-31-25 07:07AM	Insiders Are Snapping Up These 2 Stocks and Analysts Like What They See (TipRanks)
07:00AM	Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 (Business Wire)
Oct-30-25 09:39PM	Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 (Insider Monkey)
Oct-28-25 06:43PM	Why Wall Street Is Backing These 3 Comeback Stocks (MarketBeat)
03:21PM	Insiders Are Buying These 3 Stocks Hand Over Fist (24/7 Wall St.)
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
Oct-27-25 05:51AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-25-25 09:45AM	Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech (24/7 Wall St.)
Oct-24-25 07:00PM	Summit Therapeutics: A Risky Bet in the Biotech Arena? (Motley Fool)
04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks) -6.46%
09:24AM	Company News for Oct 21, 2025 (Zacks)
05:53AM	Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab (Insider Monkey)
Oct-20-25 03:00PM	Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com)
06:45AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 (Business Wire)
05:13AM	Summits dual-acting drug scores lung cancer win (BioPharma Dive)
Oct-19-25 10:30AM	Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China (Business Wire)
07:33AM	Tesla, Netflix set to report earnings as US-China trade fight turns 'unsustainable': What to watch this week (Yahoo Finance)
Oct-17-25 07:00AM	Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer (Business Wire)
Oct-15-25 07:00AM	Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 (Business Wire)
Oct-08-25 12:57AM	Where is Summit Therapeutics (SMMT) Headed According to Analysts? (Insider Monkey)
Oct-07-25 08:27AM	Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock? (Zacks)
Oct-05-25 09:45AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-02-25 01:35AM	H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones (Insider Monkey)
Oct-01-25 01:39PM	Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 (Insider Monkey)
Sep-24-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.05%
07:00AM	HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 (Business Wire)
Sep-22-25 10:21AM	Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds? (Zacks)
Sep-18-25 11:25PM	Jim Cramer on Summit Therapeutics: "We're Going to Have to Move On" (Insider Monkey) +6.30%
10:41AM	Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China (Insider Monkey)
Sep-12-25 07:57PM	Lightning Round: Ring the register on Opendoor, don't be in a meme stock, says Jim Cramer (CNBC TV)
Sep-11-25 10:05AM	Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock? (Zacks) +5.65%
Sep-10-25 12:59AM	Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating (Insider Monkey) -6.48%
Sep-09-25 01:17PM	SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study (Zacks)
05:58AM	S&P Futures Tick Higher Ahead of U.S. Payrolls Revisions (Barchart)
05:51AM	Is Summit Therapeutics a Buy, Sell, or Hold Now? (Motley Fool)
Sep-08-25 06:12PM	Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health (TheStreet) -25.15%
04:08PM	Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch (Investor's Business Daily)
11:26AM	Stock Market Today: Stocks rise as investors embrace supersized cut chances (TheStreet)
09:33AM	Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics (Yahoo Finance Video)
08:28AM	Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences (Benzinga)
07:53AM	New Summit data clouds approval pathway in lung cancer (BioPharma Dive)
Sep-07-25 03:30AM	Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC (Business Wire)
Sep-05-25 09:35AM	Apple upgraded, AMD downgraded: Wall Streets top analyst calls (TipRanks) +9.16%
Sep-04-25 09:33AM	Apple upgraded, AMD downgraded: Wall Street's top analyst calls (The Fly)
Sep-03-25 07:00AM	Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025 (Business Wire)
Aug-31-25 06:45AM	3 No-Brainer Stocks to Buy Right Now (Motley Fool)
12:10AM	H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44 (Insider Monkey)
Aug-27-25 08:07AM	Stock Market Today: Stocks rise ahead of Nvidia's after hour earnings (TheStreet) -8.06%
Aug-19-25 09:06AM	Can Keytruda Sustain Merck's Growth Through the Rest of 2025? (Zacks)
Aug-18-25 11:43PM	Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism (Insider Monkey)
Aug-17-25 06:42AM	3 Fantastic Growth Stocks to Buy in August (Motley Fool)
Aug-14-25 07:00AM	Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 (Business Wire)
Aug-13-25 12:49PM	Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call (Insider Monkey)
Aug-12-25 11:43AM	SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus (Zacks) -9.08%
Aug-11-25 05:03PM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 (Business Wire)
09:17AM	Merck Stock Down 4% Since Q2 Results: How to Play the Stock (Zacks)
Jul-28-25 04:00AM	Could bispecifics unseat Keytruda from its oncology throne? (Pharma Voice)
Jul-25-25 08:27AM	Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results? (Zacks)
Jul-22-25 04:14AM	3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results (Motley Fool)
Jul-21-25 10:00AM	This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich (Motley Fool)
12:07AM	3 Monster Stocks in the Making to Buy Right Now (Motley Fool)
Jul-17-25 03:55PM	Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings (Insider Monkey)
Jul-14-25 11:08AM	Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits? (Zacks)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
Jul-11-25 08:19AM	Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? (Zacks)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xia Yu	Director	Oct 21 '25	Buy	18.74	533,617	9,999,983	32,057,147	Oct 23 09:06 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:08 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:06 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:36 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:36 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:32 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:32 PM
Zanganeh Mahkam	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 05:01 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 04:55 PM

PLSE

Pulse Biosciences Inc

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience